Ozmosi | GXV-813 Drug Profile

Product Description

Mechanisms of Action: M4 Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Company: Novartis
Company Location: Europe
Company Founding Year: 1996
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for GXV-813

Countries in Clinic: Bulgaria, United States

Active Clinical Trial Count: 2

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: Schizophrenia

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success	Latest Trial Update Date	Data Updated
NCT07467993	STAR-1	P2	Recruiting	Schizophrenia	2027-07-29	52%	2026-06-27	Primary Endpoints
2025-524058-32-00	CGXV813B12201	P2	Not yet recruiting	Schizophrenia	2027-04-27

Recent News Events

Date	Type	Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

GXV-813

Alternative Names: GXV-813, GXV 813, GXV813, EXA8078, EXA-8078, EXA 8078, QSC205601 Clinical Status: Active Latest Update: 2026-06-26 Latest Update Note: Clinical Trial Update